These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1716470)

  • 21. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
    Sunderland T; Tariot PN; Cohen RM; Newhouse PA; Mellow AM; Mueller EA; Murphy DL
    Psychopharmacology (Berl); 1987; 91(3):293-6. PubMed ID: 2436247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF monoamine metabolites of depressed patients during illness and after recovery.
    Träskman-Bendz L; Asberg M; Bertilsson L; Thorén P
    Acta Psychiatr Scand; 1984 Apr; 69(4):333-42. PubMed ID: 6202099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased concentrations of the monoamine metabolites homovanillic acid and 5-hydroxyindoleacetic acid in lumbar and central CSF and of 3-methoxy-4-hydroxyphenylglycol in lumbar CSF after subarachnoid haemorrhage.
    von Holst H; Lindquist C; Sedvall G
    Acta Neurochir (Wien); 1985; 77(3-4):146-51. PubMed ID: 2416192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects.
    Nybäck H; Nyman H; Blomqvist G; Sjögren I; Stone-Elander S
    J Neurol Neurosurg Psychiatry; 1991 Aug; 54(8):672-8. PubMed ID: 1719135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.
    Martignoni E; Bono G; Blandini F; Sinforiani E; Merlo P; Nappi G
    J Neural Transm Park Dis Dement Sect; 1991; 3(1):15-25. PubMed ID: 1712206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects.
    Redmond DE; Katz MM; Maas JW; Swann A; Casper R; Davis JM
    Arch Gen Psychiatry; 1986 Oct; 43(10):938-47. PubMed ID: 2428328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF amine metabolites in depression.
    Reddy PL; Khanna S; Subhash MN; Channabasavanna SM; Rao BS
    Biol Psychiatry; 1992 Jan; 31(2):112-8. PubMed ID: 1371076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features.
    Kaye JA; May C; Daly E; Atack JR; Sweeney DJ; Luxenberg JS; Kay AD; Kaufman S; Milstien S; Friedland RP
    Neurology; 1988 Apr; 38(4):554-7. PubMed ID: 2451190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kawakatsu S; Morinobu S; Shinohara M; Totsuka S; Kobashi K
    Biol Psychiatry; 1990 Sep; 28(5):387-400. PubMed ID: 1698467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF levels of neurotransmitters in Alzheimer-type dementia. Effects of ergoloid mesylate.
    Seeldrayers P; Messina D; Desmedt D; Dalesio O; Hildebrand J
    Acta Neurol Scand; 1985 May; 71(5):411-4. PubMed ID: 2409733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The TRH stimulation test in Alzheimer's disease and major depression: relationship to clinical and CSF measures.
    Molchan SE; Lawlor BA; Hill JL; Mellow AM; Davis CL; Martinez R; Sunderland T
    Biol Psychiatry; 1991 Sep; 30(6):567-76. PubMed ID: 1932406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system.
    Jibson M; Faull KF; Csernansky JG
    Biol Psychiatry; 1990 Oct; 28(7):595-602. PubMed ID: 1699614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoamine metabolites in cerebrospinal fluid during acute cerebral ischemia.
    Tang HZ; Lu XF; Wang KJ; Ou YS; Huang YQ
    Chin Med J (Engl); 1989 Jan; 102(1):18-23. PubMed ID: 2475306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit.
    Mann JJ; Stanley M; Neophytides A; de Leon MJ; Ferris SH; Gershon S
    Neurobiol Aging; 1981; 2(1):57-60. PubMed ID: 7266742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated CSF dynorphin A [1-8] in Tourette's syndrome.
    Leckman JF; Riddle MA; Berrettini WH; Anderson GM; Hardin M; Chappell P; Bissette G; Nemeroff CB; Goodman WK; Cohen DJ
    Life Sci; 1988; 43(24):2015-23. PubMed ID: 2463450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection.
    Scheinin M; Chang WH; Kirk KL; Linnoila M
    Anal Biochem; 1983 May; 131(1):246-53. PubMed ID: 6193730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
    Hjärpe J; Söderman E; Andreou D; Sedvall GC; Agartz I; Jönsson EG
    Psychiatry Res; 2018 May; 263():30-34. PubMed ID: 29482043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.